Key Highlights

  • Ascendis Pharma traded at US$228.41, against a consensus target of US$315.61.
  • The median target of US$326 implies roughly +42.7% upside from the current price.
  • Targets span US$264 to US$355, framing the range of analyst opinion.
  • The consensus implies +38.2% upside, reflecting the balance of current analyst views.

Ascendis Pharma (NASDAQ:ASND) traded at US$228.41 as of 8 October 2026, against an analyst consensus price target of US$315.61, an implied upside of approximately +38.2%.

What Is the Latest Analyst Price Target?

A data provider screener as at 8 October 2026 shows a mean price target of $315.61 and a median of $326. The lowest target is $264 and the highest is $355. Using the $228.41 price, the consensus target suggests potential upside of 38.2%. The stock carries a trailing price-to-earnings ratio of 18.21, and the company does not pay a dividend. The median sitting above the mean indicates that a few lower forecasts are pulling the average down slightly.

What Are Analysts Saying?

Individual broker actions, the number of analysts covering the stock and index membership were not part of this week's verified data set. The most striking feature of the range is that even the lowest target of $264 is above the current price, by about 15.6%. In other words, every forecast captured by the provider sits higher than the shares. That is unusual and can mean either that the market is discounting risks analysts are not, or that targets have lagged a share price that has moved lower. The Strong buy label reinforces the positive lean, though it is not a guarantee.

What Could Help the Stock Reach the Price Target?

Analysts currently expect the commercial rollout of the company's approved products to be the central driver. The company has positioned itself in endocrinology and rare disease, where long-acting versions of established treatments can offer convenience for patients. If sales of its marketed medicines keep growing and its pipeline progresses, the profit base could broaden, supporting a rerating towards the mean target. Positive clinical readouts, additional regulatory approvals or new geographic launches would be the sort of developments that could narrow the gap. Building a more diversified portfolio rather than depending on one product is a theme analysts often view as important for durability.

What Could Prevent the Stock Reaching the Target?

Biotechnology shares can move sharply on clinical or regulatory news, and a setback in a trial or a delayed approval could quickly erode confidence. Reimbursement negotiations with insurers and health systems can limit pricing, while competing therapies from larger drugmakers pose a constant threat. Heavy reliance on a small number of products concentrates risk, and Manufacturing or Supply issues would matter. As a foreign issuer reporting in a different currency, exchange-rate swings can also affect results, and sector-wide sentiment toward biotechnology can shift independently of company news.

What Should Investors Watch Next?

Investors may wish to track the next quarterly results and any guidance, paying attention to uptake of the company's key medicines and the trajectory of operating profit. Pipeline milestones, including trial data and regulatory decisions, are likely to be the most important catalysts for a company of this type. Updates on reimbursement and international launches are also relevant. Since every target in the data set sits above the price, watching whether forecasts are trimmed or the share price recovers will be informative. Currency movements between the Danish krone, the euro and the dollar can also colour reported figures.

Where the Target Debate Stands for Ascendis Pharma

Ascendis Pharma (ASND) was priced at US$228.41 against a consensus target of US$315.61, an implied upside of approximately +38.2%. The median target of US$326 and the range of US$264 to US$355 frame the debate among analysts.